Quadrant Capital Group’s Gossamer Bio GOSS Stock Holding History

Quadrant Capital Group’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-28	Closed	–	–	2607
2022 Q1	$0	Hold	28	–	–	﹤0.01%	2564
2021 Q4	$0	Hold	28	–	–	﹤0.01%	2579
2021 Q3	$0	Buy	+28	New	+$258	﹤0.01%	2548

Other funds holding GOSS

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Quadrant Capital Group's GOSS Position: Q2 2022 in Review

Quadrant Capital Group sold out of Gossamer Bio (GOSS) in Q2 2022, closing a stake of 28 shares.

Quadrant Capital Group first reported a position in GOSS in Q3 2021 and held it in 3 quarters. The position peaked at $0 in Q1 2022. 129 funds tracked by Wall St. Rank hold GOSS as of Q2 2022.

Quadrant Capital Group reported no remaining Gossamer Bio position as of Q2 2022 after selling out during the quarter.
Quadrant Capital Group sold 28 Gossamer Bio shares in Q2 2022.
Quadrant Capital Group first reported a position in Gossamer Bio in Q3 2021 and held it in 3 quarters.
Quadrant Capital Group's Gossamer Bio position peaked at $0 in Q1 2022.
129 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2022.

Based on Quadrant Capital Group's 13F filing for Q2 2022, filed 9 Aug 2022.